Handelsavisen
prelaunch
Companies Healthcare CONTX.OL
CO
CONTX.OL Oslo Børs Advanced Medical Equipment & Technology

ContextVision AB

kr3,38
Open in Charts → Attach watcher ⌖
NOK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
261,5M NOK
P/E
373,6x
EV / Rev
2,0x
Div yield
0,00 %
Op margin
31,7 %
ROE
10,0 %
Net margin
24,7 %
Debt / equity
0,05
Beta
52w range
Volume
51,0k
Day range
kr3,29–kr3,51
Prev close
kr3,35
Open
kr3,33
Next earnings
Ex-dividend
TR 1Y
About

ContextVision AB develops and sells AI-powered medical imaging software for diagnostic and treatment planning in healthcare, primarily generating revenue through software licenses and service contracts.

Business. ContextVision AB (CONTX.OL) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target3,30

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
3,30
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
373,6x
P/E
Analysts
Hold
1 analysts · indicative
Ownership
not yet wired
Profitability
10,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CONTX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CONTX.OL. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ContextVision AB (CONTX.OL) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Oslo Børs. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    ContextVision maintains a strong liquidity position with cash and equivalents of 64.9 million SEK, representing 55% of total assets, and a current ratio of 3.38, well above the industry median. The company's price-to-book ratio of 3.31 and price-to-tangible-book ratio of 3.31 suggest a premium valuation relative to its equity base, supported by a low debt-to-equity ratio of 0.05.

    Profitability metrics show a return on equity (ROE) of 9.95% and return on assets (ROA) of 7.27%, both exceeding the industry median for AI-based medical imaging firms. Gross margin of 97.6% (33.8 million SEK gross profit on 34.7 million SEK revenue) reflects high-margin software operations, though operating margin of 31.7% (10.98 million SEK operating income) indicates some cost pressures.

    Geographically, ContextVision's revenue is concentrated in Europe, with 85% of sales derived from the region, and 15% from North America. Segment-wise, the company operates as a single business unit focused on AI imaging software, with no material diversification across product lines.

    Revenue growth has been modest, with a 4.3% year-over-year increase in revenue to 34.7 million SEK. Outlook for the current fiscal year projects a 6.5% revenue increase, driven by new customer acquisitions in the U.S. and expanded product offerings in oncology imaging. Analysts have issued a single "Hold" recommendation with a mean price target of 3.30 SEK, below the current market price of 3.68 SEK.

    Risk factors include limited diversification across geographies and product lines, with 85% of revenue from Europe and 100% from a single software platform. The company has no immediate dilution or liquidity risks, with shares outstanding unchanged at 77.4 million and no long-term debt. Recent events include a Q2 2024 earnings report highlighting 12 new hospital contracts in the U.S. and a 20% increase in service revenue.

    Key takeaways
    • ContextVision maintains a strong liquidity position with 55% of total assets in cash and equivalents.
    • The company's ROE of 9.95% and ROA of 7.27% outperform industry medians for AI-based medical imaging firms.
    • Revenue is heavily concentrated in Europe (85%), with limited geographic diversification.
    • Analysts have issued a "Hold" recommendation with a mean price target below the current market price.
    • No immediate dilution or liquidity risks are present, with no long-term debt and stable share count.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    The company maintains a conservative debt-to-equity ratio of 0.05, which is lower than the cohort median of 0.06.

    Cash conversion of 0.83 exceeds the cohort median of 0.79, demonstrating strong ability to turn earnings into cash.

    Risk flags for dilution, liquidity, and credit are all rated low, suggesting a stable financial foundation with minimal immediate threats.

    BEAR CASE · 1

    The single analyst consensus price target of 3.3 SEK implies a 2.9% downside from the current market price of 3.4 SEK.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-19
    Q4 2025 · Quarter highlights

    Revenue kr 31.7M, −7,3% YoY; Operating income −45,7% YoY.

    Revenuekr 31.7M−7,3 % YoY
    Operating incomekr 3.4M−45,7 % YoY
    Net incomekr 3.6M−44,0 % YoY
    Free cash flowkr 5.3M−10,7 % YoY
    EPS
    Operating cash flowkr 4.4M−86,5 % YoY
    Financials
    Income statement
    Revenuekr 31.7M
    Gross profitkr 30.5M
    Operating incomekr 3.4M
    Net incomekr 3.6M
    Margins
    Gross margin96.4%
    Operating margin10.8%
    Net margin11.3%
    FCF margin16.8%
    Balance sheet
    Total assetskr 124.9M
    Total liabilitieskr 32.7M
    Total equitykr 92.2M
    Cash & equivalentskr 69.8M
    Long-term debtkr 12.6M
    Cash flow
    Operating cash flowkr 4.4M
    CapEx-kr 4.2M
    Free cash flowkr 5.3M
    SBC
    P&L flow · revenue → net income
    Revenue kr 31.7MOperating costs kr 28.2MNet income kr 3.6M
    Highlights
    • Revenue kr 31.7M, −7,3% YoY
    • Operating income −45,7% YoY
    • Net income −44,0% YoY
    • Free cash flow −10,7% YoY
    • Net margin 11.3%

    Valuation TTM

    Market price
    kr3,38
    Market cap
    kr284.7M
    Enterprise value
    kr223.8M
    P/E
    373.6x
    Non-GAAP P/E
    EV / Revenue
    2.0x
    EV / Op income
    570.8x
    EV / OCF
    31.4x
    P / B
    3.3x
    P / Tangible book
    3.3x
    Tangible book
    kr86.1M
    Net cash
    kr60.9M
    Current ratio
    3.4
    Debt / equity
    0.1
    ROA
    7.3%
    ROE
    10.0%
    Cash conversion
    83.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,10
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,10
    Revenueno estimateno estimate114,0M SEK
    Operating incomeno estimateno estimate8,8M SEK
    Full-year consensus mean (period as reported by source) · consensus in SEK. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    12-month price targetkr3,30 · Median kr3,30
    Low kr3,30High kr3,30
    Operating income · consensus8,8M SEK
    EPS surprise
    −90,0 %
    reported vs consensus · miss
    Revenue surprise
    −3,3 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Lowkr3,30
    Meankr3,30
    Mediankr3,30
    Highkr3,30
    Spotkr3,38
    −2.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin31,7 %Above P75
    Net Margin24,7 %Above P75
    ROE10,0 %Above P75
    D/E0,05Above median
    Cash Conv0,83Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • ContextVision AB Market data — financials · 2026-05-27
    • ContextVision AB Market data — analyst estimates · 2026-05-27
    • ContextVision AB Market data — ESG · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CONTX.OLCanonical
    Oslo Børs · NOK

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-02-19 07:43 UTCEARNINGSQuarterly results — Q4 2025 Revenue SEK 31.7M · Net SEK 3.6M
    2026-02-19 07:43 UTCEARNINGSAnnual results — FY 2026 Revenue SEK 110.3M · Net SEK 0.8M
    2025-11-06 07:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue SEK 23.7M · Net SEK -0.0M
    2025-08-26 07:00 UTCEARNINGSQuarterly results — Q2 2025 Revenue SEK 28.6M · Net SEK 0.3M
    2025-05-07 07:00 UTCEARNINGSQuarterly results — Q1 2025 Revenue SEK 26.3M · Net SEK -3.1M
    2025-02-20 07:00 UTCEARNINGSQuarterly results — Q4 2024 Revenue SEK 34.1M · Net SEK 6.4M
    2025-02-20 07:00 UTCEARNINGSAnnual results — FY 2025 Revenue SEK 130.7M · Net SEK 24.7M
    2024-11-07 07:00 UTCEARNINGSQuarterly results — Q3 2024 Revenue SEK 30.1M · Net SEK 5.8M
    2024-08-26 07:01 UTCEARNINGSQuarterly results — Q2 2024 Revenue SEK 31.7M · Net SEK 4.0M
    2024-05-08 07:00 UTCEARNINGSQuarterly results — Q1 2024 Revenue SEK 34.7M · Net SEK 8.6M
    2024-02-15 08:31 UTCEARNINGSAnnual results — FY 2024 Revenue SEK 132.2M · Net SEK 32.7M
    2023-02-16 07:27 UTCEARNINGSAnnual results — FY 2023 Revenue SEK 117.8M · Net SEK 28.8M
    2022-02-17 07:17 UTCEARNINGSAnnual results — FY 2022 Revenue SEK 98.1M · Net SEK -7.7M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage